Angiographic findings and clinical correlates in patients with cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry  by Wong, S.Chiu et al.
Angiographic Findings and Clinical
Correlates in Patients With Cardiogenic
Shock Complicating Acute Myocardial
Infarction: A Report from the SHOCK Trial Registry
S. Chiu Wong, MD, FACC,* Timothy Sanborn, MD,* Lynn A. Sleeper, SCD,† John G. Webb, MD,‡
Robert Pilchik, MD,§ David Hart, MD,§ Slawomir Mejnartowicz, MD,§ Tracy A. Antonelli, MPH,†
Richard Lange, MD,\ John K. French, MB, CHB, PHD,¶ Geoffrey Bergman, MD,*
Thierry LeJemtel, MD, FACC,** Judith S. Hochman, MD, FACC,§ for the SHOCK Investigators
New York, New York; Watertown, Massachusetts; Vancouver, British Columbia, Canada; Dallas, Texas; Auckland,
New Zealand; Bronx, New York
OBJECTIVES We sought to delineate the angiographic findings, clinical correlates and in-hospital outcomes
in patients with cardiogenic shock (CS) complicating acute myocardial infarction.
BACKGROUND Patients with CS complicating acute myocardial infarction carry a grave prognosis. Detailed
angiographic findings in a large, prospectively identified cohort of patients with CS are
currently lacking.
METHODS We compared the clinical characteristics, angiographic findings, and in-hospital outcomes of
717 patients selected to undergo angiography and 442 not selected, overall and by shock
etiology: left or right ventricular failure versus mechanical complications.
RESULTS Patients who underwent angiography had lower baseline risk and a better hemodynamic
profile than those who did not. Overall, 15.5% of the patients had significant left main lesions
on angiography, and 53.4% had three-vessel disease, with higher rates of both for those with
ventricular failure, compared with patients who had mechanical complications. Among
patients who underwent angiography, those with ventricular failure had significantly lower
in-hospital mortality than patients with mechanical complications (45.2% vs. 57.0%; p 5
0.021). Importantly, for patients with ventricular failure, in-hospital mortality also correlated
with disease severity: 35.0% for no or single-vessel disease versus 50.8% for three-vessel
disease. Furthermore, mortality was associated with the culprit lesion location (78.6% in left
main lesion, 69.7% in saphenous vein graft lesions, 42.4% in circumflex lesions, 42.3% in left
anterior descending lesions, and 37.4% in right coronary artery lesions), and Thrombolysis In
Myocardial Infarction (TIMI) flow grade (46.5% in TIMI 0/1, 49.4% in TIMI 2 and 26%
in TIMI 3).
CONCLUSIONS Patients who underwent angiographic study in the SHOCK Trial Registry had a more benign
cardiac risk profile, more favorable hemodynamic findings and lower in-hospital mortality
than those for whom angiograms were not obtained. Patients with CS caused by ventricular
failure had more severe atherosclerosis, and a different distribution of culprit vessel
involvement but lower in-hospital mortality, than those with mechanical complications.
Overall in-hospital survival correlates with the extent of coronary artery obstructions, location
of culprit lesion and baseline coronary TIMI flow grade. (J Am Coll Cardiol 2000;36:
1077–83) © 2000 by the American College of Cardiology
For the past two decades, the incidence of cardiogenic shock
(CS) in acute myocardial infarction (AMI) has remained
stable, involving 5% to 15% of patients hospitalized for
AMI (1–4). Despite the introduction of specialized care
units, the advent of potent pharmacological agents, and
refinements in mechanical interventions, the prognosis of
patients with CS complicating AMI remains poor (5–7).
Importantly, conventional treatment with intravenous
thrombolytics does not substantially improve in-hospital
mortality in patients with AMI once CS is diagnosed (8,9).
Recent observational studies have shown that early, ag-
gressive interventions may translate into improved early
clinical outcomes in these patients (10–16). Furthermore,
retrospective, nonrandomized studies consistently have re-
ported an encouraging effect on mortality with revascular-
ization strategies in this cohort (17–19). Consequently,
knowledge of coronary angiographic findings may help
formulate more rational therapeutic strategies to improve
clinical outcomes in these patients. However, there are few
data that describe the coronary anatomy, including the
extent of coronary obstructions, location of culprit vessels,
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and status of coronary flow, in a large, prospectively col-
lected database of patients with CS.
The “SHould we emergently revascularize Occluded Cor-
onaries for cardiogenic shocK?” (SHOCK) Trial was a
multicenter study of emergency revascularization in patients
with AMI complicated by CS. In an effort to ensure that all
potentially eligible patients were screened for the study and
to minimize enrollment bias, all patients with clinical or
hemodynamic evidence of CS complicating AMI, but not
enrolled in the randomized trial, were entered into a registry
(6). The SHOCK Trial Registry provides a unique database
to evaluate the cardiovascular anatomy, angiographic find-
ings and clinical correlates in these patients.
METHODS
Patients. Thirty-six enrolling centers registered 1,190 pa-
tients with suspected CS complicating AMI who were
either ineligible for the randomized SHOCK Trial or
eligible and not randomized from April 1993 to August
1997. A detailed description of the SHOCK Trial Registry
methodology is reported in this supplementary issue of the
Journal (6). A local discharge diagnosis of AMI with CS
(DRGs 410, 410.1 to 410.9, in conjunction with 785.51)
constituted criteria for being registered. Seven hundred and
thirty patients (61%) were registered in 24 U.S. centers; 256
(22%) in five Canadian centers; 76 (6%) in four Belgian
centers; and 128 (11%) in Australia, New Zealand and
Brazil. Reports were not available for 31 of the angiography
patients, and this report is therefore based on a total of
1,159 SHOCK Trial Registry patients.
Data collection. Data were abstracted from medical
records by SHOCK study coordinators, who were centrally
trained to complete standard report forms. They captured
patient and MI characteristics, hemodynamics, procedure
use, and vital status at discharge. Cardiac catheterization
reports from all investigation sites were sent to the Clinical
Coordinating Center for abstraction and central completion
of a standardized report form that included the extent of
coronary artery obstructions, degree of lesion severity, cul-
prit lesion location, Thrombolysis In Myocardial Infarction
(TIMI) flow characteristics and ejection fraction. Not all of
these variables were available on all patients; the sample size
for each variable is noted in the tables.
Definitions. Predominant left ventricular (LV) failure was
designated as the etiology of shock when none of the
following was indicated: isolated right ventricular (RV)
shock, mechanical cause (acute severe mitral regurgitation
[MR] or ventricular septal rupture [VSR]), tamponade,
prior severe valvular heart disease, excess beta or calcium-
channel blockade, or shock resulting from a catheterization
laboratory complication.
Re-infarction was defined as: 1) recurrent chest pain or
ischemic symptoms $30 min and recurrent ST-segment
elevation, new Q waves, or new left bundle branch block; 2)
total creatine kinase (CK) at least twice the upper limit of
normal and .25% or 200 U/mL over the previous value
with an elevated CK-MB level; or 3) a rise in CK-MB
above the upper limit of normal after it had reverted to the
normal range.
The description of coronary blood flow varied from center
to center. Thrombolysis In Myocardial Infarction flow
grades 0 to 3 were recorded as stated. If no TIMI flow grade
was specified, an assessment was made based on the infor-
mation provided and the following pre-specified criteria: a
statement that there was no antegrade flow or total occlu-
sion or 100% stenosis were set to TIMI grade 0 to 1;
sluggish flow or subtotal occlusion, including 95% to 99%
stenosis, were set to TIMI grade 2; normal flow or patent or
,95% stenoses were set to TIMI grade 3. This method may
systematically categorize some patients with TIMI 3 flow as
TIMI 2.
Statistical methods. The clinical characteristics, etiologies
of CS and hemodynamic findings of the 717 patients with
available angiographic results were compared with those of
the 442 who did not undergo angiography (total, n 5
1,159). In a subset analysis, the angiographic and clinical
findings were compared between patients with LV or RV
failure and those with a mechanical cause of shock. Angio-
graphic correlations with clinical outcomes were examined
in more detail in patients with pump (LV or RV) failure
because they accounted for most of the patients (77.9%)
who developed CS after AMI.
Groups were compared using the Fisher exact test for
categorical variables, the Wilcoxon rank-sum test for ordinal
and non-normally distributed continuous variables and the
Student t-test for normally distributed continuous variables.
When three ordered groups were being compared, variables
were evaluated using the Mantel-Haenszel test for linear
trend. All analyses were conducted using SAS (SAS Insti-
tute, Cary, North Carolina).
RESULTS
Patient characteristics (Table 1). Of the 1,190 patients in
the SHOCK Trial Registry, 748 patients (63%) underwent
angiography, and results were available for 717 patients.
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CAD 5 coronary artery disease
CK(-MB) 5 creatine phosphokinase (-MB)
CS 5 cardiogenic shock
IABP 5 intra-aortic balloon pump
LAD 5 left anterior descending
LV 5 left ventricular, left ventricle
MR 5 mitral regurgitation
RV 5 right ventricular, right ventricle
SHOCK 5 SHould we emergently revascularize
Occluded Coronaries for cardiogenic
shocK? (Trial)
TIMI 5 Thrombolysis In Myocardial Infarction
VSR 5 ventricular septal rupture
1078 Wong et al. JACC Vol. 36, No. 3, Suppl A
Angiographic and Clinical Factors in CS September 2000:1077–83
Hence, the size of the SHOCK Trial Registry cohort for
these analyses is 1,159. Compared with the 442 patients
who did not undergo angiography, patients with angio-
graphic data had a more favorable risk profile; they were
younger and had a lower incidence of prior MI, hyperten-
sion, diabetes, prior congestive heart failure, renal insuffi-
ciency and peripheral vascular disease.
Etiology of CS (Table 2). Mechanical complications of
MI were responsible for the development of CS in 12.5% of
the patients in this SHOCK Trial Registry cohort, whereas
predominant RV or LV failure was diagnosed in 77.9%.
Indeed, LV failure was the most frequent cause of CS
(74.5%). Compared with patients who did not undergo
angiography, the angiographic cohort had a higher rate of
mechanical complications (14.6% vs. 9.1%, p , 0.001). The
in-hospital mortality of patients who underwent angiogra-
phy (47.3%) was markedly lower than those who did not
undergo angiography (86.2%).
Hemodynamic findings (Table 3). The hemodynamic
measurements closest to onset of CS were obtained for
SHOCK Trial Registry patients, with a median time from
onset of CS to right heart catheterization of 3.9 h and a
range of from 1.1 h at the first quartile to 17.7 h at the third
quartile. Patients who underwent angiography had more
favorable hemodynamics findings with higher systolic and
diastolic blood pressures, lower systolic pulmonary artery
pressure, and higher ejection fraction and cardiac index
values, compared with patients who were not selected for
angiography.
Angiographic findings (Table 4). The majority of patients
(72.4%) underwent angiography while they were in CS.
Most patients (53.4%) had three-vessel disease, and there
was a high frequency (15.5%) of significant ($50%) left
main lesions. The left anterior descending artery (LAD) was
the culprit vessel in 41.3% of cases. Thrombolysis In
Myocardial Infarction grade 0 or 1 flow in the infarct-
related artery was noted in 67% of the 494 patients with data
available. Ejection fraction (n 5 252), which was most often
obtained while the patient was receiving support measures,
was severely compromised (34.2% 6 14.4%).
Patients with ventricular failure had a higher prevalence
of triple-vessel disease (56.4% vs. 39.8%, p 5 0.029), but
there was no difference in the rate of severe left main disease
(16.2% vs. 10.9%, p 5 0.161) when compared with patients
with CS shock due to mechanical failure. The culprit vessel
was more often the LAD in the ventricular-failure cohort,
whereas the circumflex artery was more often involved in
patients with mechanical failure. In patients who received
thrombolytic therapy and had TIMI flow data available,
60% of 116 patients had TIMI grade 0 or 1 flow post
thrombolytic treatment, compared with 91% of 11 patients
Table 1. Baseline Characteristics of SHOCK Trial Registry Patients
Overall
(n 5 1,159)
Angiography Performed
Yes
(n 5 717)*
No
(n 5 442)
p
Value
Female gender 40.6% 39.9% 41.6% 0.558
Age (yrs) 68.7 6 11.8 65.8 6 11.2 73.8 6 10.9 , 0.001
History of infarction 37.3% 32.7% 44.7% , 0.001
History of hypertension 53.2% 50.6% 57.6% 0.024
Diabetes 32.6% 29.7% 37.4% , 0.001
Smoking 50.2% 52.2% 46.7% 0.097
History of angioplasty 6.2% 7.6% 3.8% , 0.001
History of bypass surgery 9.9% 9.4% 10.7% 0.467
History of congestive heart failure 20.1% 16.1% 26.5% , 0.001
History of renal insufficiency 11.0% 8.4% 15.4% , 0.001
History of peripheral vascular disease† 18.2% 16.0% 22.5% 0.033
History of elevated lipids‡ 41.9% 45.0% 35.8% 0.034
*Reflects only patients with available angiographic results (717/748); †Data available for n 5 738; ‡Data available for n 5 573.
Table 2. Etiology of CS and In-hospital Mortality
Overall
(n 5 1,159)
Angiography Performed
Yes
(n 5 717)*
No
(n 5 442)
p
Value
Predominant left ventricular failure 74.5% 73.6% 75.9% 0.375
Isolated right ventricular failure 3.4% 3.5% 3.2% 0.774
Mechanical complication† 12.5% 14.6% 9.1% , 0.001
Cardiac tamponade or rupture 2.3% 2.5% 2.0% 0.606
Severe prior valvular disease 2.9% 2.2% 4.1% 0.070
Other 6.3% 5.9% 7.0% 0.431
In-hospital Mortality 62.1% 47.3% 86.2% , 0.00001
*Reflects only patients with available angiographic results (717/748); †Ventricular septal defect or acute severe mitral
regurgitation.
1079JACC Vol. 36, No. 3, Suppl A Wong et al.
September 2000:1077–83 Angiographic and Clinical Factors in CS
whose angiograms were obtained prior to thrombolysis (p 5
0.051).
The extent of coronary artery stenoses was slightly less
severe in the SHOCK Trial Registry, compared with
patients who met strict criteria and were enrolled in the
randomized SHOCK Trial with LV failure (24): 0/1-vessel
disease, 22.4% vs. 13%; two-vessel disease, 20.7% vs. 22.6%;
three-vessel disease, 57% vs. 64.4%; p 5 0.006, and left
main, 16.1% vs. 21%; p 5 0.122 for 518 SHOCK Trial
Registry patients with predominant LV failure (excluding
patients with RV failure) and 239 SHOCK Trial patients,
respectively.
Outcomes in relation to angiographic findings in pa-
tients with ventricular failure. Patients with ventricular
failure had significantly lower in-hospital mortality than
those with a mechanical cause of shock (45.2% vs. 57%, p 5
0.021, Table 4). Their mortality increased as the severity of
disease increased, from 35% in patients with pump failure
and no or single-vessel disease at angiography to 50.8% in
such patients with three-vessel disease (p 5 0.002, Table 5).
The infarct-related artery was also associated with survival
in patients with pump failure; if the culprit vessel was the
left main or a saphenous vein graft, the associated mortality
was dismally high (78.6% and 69.7%, respectively; Table 6).
Remarkably, any subnormal TIMI flow in the culprit vessel
was associated with a poorer prognosis; only the presence of
TIMI grade 3 flow was associated with better survival in this
cohort. Percutaneous interventions were the most prevalent
for patients with single-vessel disease (75.6%), but bypass
surgery was more common in patients with more extensive
disease (Table 5). Recurrent ischemia and re-infarction
occurring between the initial MI that brought the patient to
the hospital and the onset of shock was noted in 26.9% of
patients with pump failure. This might result from a
combination of the unstable hemodynamic status and the
extensive obstructive coronary artery disease (CAD) in these
Table 3. Hemodynamic Findings Measured Close to Shock Onset While Patients Often on Mechanical or Pharmacological Support
Overall
(n 5 1,159)
Angiography Performed
Yes
(n 5 717)*
No
(n 5 442) p Value
Heart rate (beats/min) 95.7 6 26.2 (n 5 1,121) 96.7 6 24.9 (n 5 675) 93.8 6 27.3 (n 5 417) 0.091
Systolic blood pressure (mm Hg) 87.7 6 22.3 (n 5 1,124) 89.7 6 21.6 (n 5 679) 84.4 6 22.8 (n 5 417) , 0.001
Diastolic blood pressure (mm Hg) 52.3 6 17.0 (n 5 976) 53.5 6 16.5 (n 5 613) 50.0 6 17.7 (n 5 338) 0.007
PCWP (mm Hg) 23.4 6 8.4 (n 5 739) 23.3 6 8.5 (n 5 536) 23.6 6 8.5 (n 5 185) 0.512
Pulmonary artery systolic pressure (mm Hg) 41.2 6 12.8 (n 5 482) 40.3 6 12.9 (n 5 371) 44.8 6 12.3 (n 5 96) , 0.001
Left ventricular ejection fraction (%)† 32.6 6 13.8 (n 5 468) 33.5 6 13.8 (n 5 357) 28.8 6 12.5 (n 5 96) 0.003
Cardiac index (L/min/m2) 2.1 6 0.8 (n 5 562) 2.1 6 0.8 (n 5 398) 1.9 6 0.6 (n 5 149) 0.017
*Reflects only patients with available angiographic results (717/748). Right heart catheterization was performed in 79% of patients with angiogram; †Measured at any time during
the index hospitalization.
Table 4. Registry Angiographic Findings, Overall and by Shock Etiology
All*
(n 5 717)
Etiology of Shock
Mechanical
(n 5 114)
Pump
Failure
(n 5 549)
p
Value
Left main disease $50% (n 5 691) 15.5% 10.9% 16.2% 0.161
Number diseased vessels (n 5 708) 0.029
0 or 1 22.7% 24.8% 22.7%
2 23.9% 35.4% 20.9%
3 53.4% 39.8% 56.4%
Culprit vessel (n 5 552) 0.053
LAD 41.3% 33.3% 42.7%
Left circumflex 15.8% 26.9% 13.5%
Right coronary 29.5% 30.8% 29.9%
Left main 5.6% 3.9% 6.4%
Saphenous vein graft 7.8% 5.1% 7.5%
Quantitative findings
Stenosis $50% (n 5 525) 99.6% 100.0% 99.5% 0.545
TIMI grade 0/1 flow (n 5 494) 66.8% 69.3% 67.2% 0.716
Ejection fraction (%) (n 5 252)† 34.2 6 14.4 35.7 6 13.3 33.2 6 14.3 0.240
In-hospital mortality 47.3% 57.0% 45.2% 0.021
*Includes those with mechanical failure, those with left or right ventricular failure, and patients with other causes of shock; †By
left ventriculogram.
LAD 5 left anterior descending.
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critically ill patients. Importantly, no angiographic variables
were significantly associated with re-infarction.
DISCUSSION
The extensive CAD demonstrated in the SHOCK Trial
Registry is consistent with our understanding of the patho-
genesis of pump failure, which is extensive myocardial
ischemia and necrosis. Furthermore, it highlights the chal-
lenges in accomplishing restoration of normal coronary
perfusion. Cardiogenic shock remains the leading cause of
mortality in patients admitted for AMI (20,21), despite the
substantial improvements in survival that have occurred
since the introduction of thrombolytic treatment. More
recently, the combination of intra-aorta balloon pump
(IABP) and successful thrombolysis or revascularization
(percutaneous or surgical) has been shown to enhance
clinical outcomes in observational studies (22,23). The
randomized SHOCK Trial demonstrated that early revas-
cularization improved six-month survival (24). Therefore,
knowledge of angiographic findings may provide insight
into the pathogenesis of CS and suggest more rational
treatment approaches in these critically ill patients.
Angiographic findings in patients with CS. Patients se-
lected for angiography had a better risk profile than those
who did not undergo angiography. This partially accounts
for their better survival, as reported (6). In the current
analysis, the extent of CAD was significantly and inversely
related to in-hospital survival in patients with shock due to
LV or RV failure. This correlates well with the report by
Wacker et al. (25), which noted a high prevalence of severe
triple-vessel disease (75% of cases) and diffuse LAD ob-
structions (84%) at autopsy in patients who died from CS
with AMI.
In recent multicenter trials for treatment of AMI, mul-
tivessel CAD was noted in 47% to 59.4% of the patients
enrolled; left main culprit lesions were present in 0.8% to
1.7%; and vein-graft lesions constituted 1.7% to 3.9% of the
culprit lesions (26–33). Compared with these patients,
Table 5. In-hospital Mortality and Intervention Rates by Angiographic Disease Severity in
Patients with LV or RV Failure
0/1-Vessel
Disease
(n 5 123)
2-Vessel
Disease
(n 5 113)
3-Vessel
Disease
(n 5 305)
p
Value*
Mortality 35.0% 39.8% 50.8% 0.002
Percutaneous coronary intervention† 75.6% 63.7% 43.3% 0.001
Angioplasty only 72.4% 61.1% 38.0% 0.001
Bypass surgery 6.5% 15.9% 33.8% 0.001
*p value from Mantel-Haenszel test for linear trend; †Includes 23 patients with bypass surgery post angioplasty.
Table 6. In-hospital Event Rates by Angiographic Findings in Patients with LV or RV Failure
Mortality
Recurrent
Ischemia and
Re-infarction*
Overall event rate
(n 5 549, 409)
45.2% 26.9%
Number of diseased vessels p 5 0.002 p 5 0.300
0 or 1 35.0% 24.4%
2 39.8% 23.3%
3 50.8% 29.3%
Left main disease present 62.8% 25.4%
p 5 0.001 p 5 0.734
Left main disease absent 49.9% 27.3%
Infarct-related vessel p , 0.001 p 5 0.295
Right coronary 37.4% 23.7%
Circumflex 42.4% 33.3%
Left anterior descending 42.3% 26.2%
Left main 78.6% 19.1%
Saphenous vein graft 69.7% 42.3%
TIMI flow in culprit vessel p 5 0.035 p 5 0.064
0 or 1 46.5% 22.9%
2 49.4% 33.9%
3 26.0% 34.4%
Ejection fraction (%)† Dead: 32.0 6 16.2 ReMI: 36.9 6 13.4
p 5 0.245 p 5 0.163
Alive: 33.9 6 13.1 No ReMI: 31.2 6 14.4
*Collected on new forms only—409 of 549 patients. Re-infarction was defined as occurring between the initial MI causing
hospitalization and onset of shock; †By left ventriculography (data available for 179 patients).
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those in the SHOCK Trial Registry had more multivessel
disease (77.3%) and more frequent culprit left-main (5.6%)
and vein-graft lesions (7.8%). When the infarct-related
artery was the left main or a vein graft, the prognosis was
particularly poor in those with shock brought on by pump
failure.
The presence of TIMI grade 3 flow in the infarct artery
also was associated with improved survival. Perhaps normal
TIMI flow reflects not only the severity of the culprit lesion
but also the integrity of the microvasculature and viability of
the myocardium normally supplied by the culprit vessel. The
high frequency of left-main and three-vessel disease, in
conjunction with the impaired LV function in patients with
CS, justifies routine angiography for most of these patients,
based on long-term survival benefits shown with revascu-
larization for these anatomic findings. Furthermore, the
SHOCK Trial demonstrated improved six-month survival
with early revascularization, compared with initial medical
stabilization (24).
Although the majority of the eligible patients received
thrombolysis, nearly 70% of the patients who underwent
angiogram had only TIMI grade 0 or 1 flow. This finding
confirms the low reperfusion rate in patients with CS who
receive thrombolysis (34). This is particularly disconcerting,
considering the strong association of normal TIMI flow
with survival in our study. Whether more potent thrombo-
lytic agents or the combination of thrombolytics with
platelet glycoprotein IIb/IIIa antagonists would enhance
reperfusion and thus outcomes in these patients remains to
be determined.
Outcome in relation to shock etiology and angiographic
findings. Patients with ventricular failure had significantly
better in-hospital survival than those with mechanical eti-
ology of shock, despite having higher rates of left-main and
vein-graft involvement, and more multivessel disease, than
those with mechanical failure. Of note, improved survival in
patients with ventricular failure was observed only in the
cohort selected for angiography; outcomes for such patients
with severe MR were similar, and those patients with VSR
were worse (6,35,36).
Patients with LV or RV failure. Patients admitted with
shock brought on by pump failure had a high mortality rate
(45.2%), but this is lower than rates from historical reports
(2–5). This can be explained partly by the selection for
angiography and by the aggressive treatment that our
patients received (6). Indeed, over 70% of those who
underwent angiography in the SHOCK Trial Registry
received IABP and revascularization.
Study limitations. By contrast to the randomized SHOCK
Trial, the angiograms obtained in the SHOCK Trial Registry
patients were not analyzed in a core laboratory, but were
reviewed during central completion of standardized report
forms based on local laboratory reports. Although our data
demonstrated that TIMI flow grade has important prognostic
value in patients with CS, the absence of a central core lab
analysis and overall hemodynamic status of these critically ill
patients at the time of catheterization may have affected the
overall TIMI flow findings. Patients enrolled in the SHOCK
Trial Registry were those who failed to meet all the pre-
specified stringent enrollment criteria or refused participation
in the multicenter randomized trial, and the decision to obtain
angiography in these patients was largely dictated by the
patients’ personal physicians. These confounding variables
clearly would affect the angiographic findings in this analysis.
Indeed, patients in the SHOCK Trial Registry seem to have
less extensive coronary artery obstructions, compared with
those enrolled in the randomized trial with its more stringent
enrollment criteria. On the other hand, the less stringent
enrollment criteria in the SHOCK Trial Registry patients also
makes the angiographic findings closer to the “real-world”
findings derived from everyday practices in catheterization
laboratories.
Conclusions. Patients selected by their physicians for an-
giography in the SHOCK Trial Registry had a lower-risk
profile than those who did not undergo angiography.
Overall, patients in the SHOCK Trial Registry had a high
prevalence of left-main and diffuse triple-vessel disease.
Patients with different etiologies for CS have different
clinical characteristics and angiographic findings. Patients
with a mechanical cause of shock had a lower rate of
three-vessel disease. Despite these findings, these patients
had higher mortality than did those with shock due to
ventricular failure.
For patients with CS brought on by pump failure, in
addition to the extent of coronary artery obstructions, infarct-
related vessel and baseline TIMI flow were also found to have
significant prognostic value for these patients. Importantly, if
either the left main or a vein graft was the culprit vessel, the
prognosis was particularly poor, with in-hospital mortality of
;70%. On the other hand, patients with initial TIMI grade 3
flow in the infarct vessel had substantially better in-hospital
survival than those with TIMI grade 0 or 1 flow. Thus, timely
angiographic studies would be helpful in the management and
prognostication of these patients.
Although survival in patients with CS complicating AMI
remains poor, an aggressive treatment approach (including a
combination of more potent thrombolytic agents, platelet
glycoprotein IIb/IIIa inhibitors, early placement of an IABP
and emergency percutaneous or surgical reperfusion strate-
gies) may further improve TIMI flow and hence clinical
outcomes in these complex, critically ill patients.
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